Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.
Epistemonikos ID: efd7af3edd478aa365f26cc8408fdf83e4a21302
First added on: May 15, 2024